Analysis of FoxP3+ T-regulatory cells and CD8+T-Cells in ovarian carcinoma: Location and tumor infiltration patterns are key prognostic markers

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Hermans, Cecilia ^a   Anz, David ^a   Engel, Jutta ^a   Kirchner, Thomas ^a   Endres, Stefan ^a   Mayr, Doris ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FOXP3; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CELL AGGREGATION; CELLULAR DISTRIBUTION; EFFECTOR CELL; FEMALE; FOXP3+ REGULATORY T LYMPHOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE; SURVIVAL TIME; VERY ELDERLY; CELLULAR IMMUNITY; IMMUNOLOGY; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNITY, CELLULAR; MIDDLE AGED; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES, REGULATORY;

EID: 84909619958     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0111757     Document Type: Article

References (57)

1. WHO WHO (2009) World Health Observatory. Geneva: World Health Organization.
2. Fachgesellschaften AdWM (2007) Diagnostik und Therapie maligner Ovarialtumoren. AWMF.
3. Tavassoli FA, Devilee P, editors (2004) Pathology & Genetics: Tumours of the Breast and Female Genital Organs: World Health Organization Classification of Tumours.
4. Koch-Institut R (2010) Verbreitung von Krebserkrankungen in Deutschland. Entwicklung der Prävalenzen zwischen 1990 und 2010. Beiträge zur Gesundheitsberichterstattung des Bundes. Berlin: Robert Koch Institut.
5. Woodward ER, Sleightholme HV, Considine AM, Williamson S, McHugo JM, et al. (2007) Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. Bjogan International Journal of Obstetrics and Gynaecology 114:1500-1509.
6. DeutscheKrebsgesellschaft (2006) Interdisziplinäre S2k-Leitlinie für die Diagnostik und Therapie maligner Ovarialtumore. München: W. Zuckschwerdt Verlag. pp. 76.
7. Schmalfeldt B, editor (2007) Manual maligne Ovarialtumore. München: Tumorzentrum München und W. Zuckschwerdt Verlag München. 124 p.
8. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, et al. (1993) Prevalence Screening for Ovarian-Cancer in Postmenopausal Women by Ca 125 Measurement and Ultrasonography. British Medical Journal 306:1030-1034.
9. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, et al. (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine 348:203-213.
10. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, et al. (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4:e6412.
11. North RJ, Bursuker I (1984) Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2-suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med 159:1295-1311.
12. Awwad M, North RJ (1988) Immunologically mediated regression of a murine lymphoma after treatment with anti-L3T4 antibody. A consequence of removing L3T4+ suppressor T cells from a host generating predominantly Lyt-2+ T cellmediated immunity. J Exp Med 168:2193-2206.
13. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM (1997) Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol 182:318-324.
14. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, et al. (2005) Intraepithelial CD8 (+) tumor-infiltrating lymphocytes and a high CD8 (+)/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America 102:18538-18543.
15. Curiel TJ, Coukos G, Zou LH, Alvarez X, Cheng P, et al. (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 10:942-949.
16. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) immunological self-tolerance maintained by activated t-cells expressing il-2 receptor alphachains (cd25) - breakdown of a single mechanism of self-tolerance causes various autoimmune-diseases. Journal of Immunology 155:1151-1164.
17. Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4 (+) CD25 (+) regulatory T cells. Nature Immunology 4:330-336.
18. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-1061.
19. Shimizu Y, Kamoi S, Amada S, Hasumi K, Akiyama F, et al. (1998) Toward the development of a universal grading system for ovarian epithelial carcinoma - I. Prognostic significance of histopathologic features - Problems involved in the architectural grading system. Gynecologic Oncology 70:2-12.
20. Wang L, Ma Q, Chen X, Guo K, Li J, et al. (2010) Clinical significance of b7-h1 and b7-1 expressions in pancreatic carcinoma. World J Surg 34:1059-1065.
21. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR (2013) Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clinical and Experimental Immunology 171:36-45.
22. Clarke SL, Betts GJ, Plant A, Wright KL, El-Shanawany TM, et al. (2006) CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS One 1:e129.
23. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, et al. (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964.
24. Facciabene A, Motz GT, Coukos G (2012) T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis. Cancer Research 72:2162-2171.
25. Chaput N, Louafi S, Bardier A, Charlotte F, Vaillant JC, et al. (2009) Identification of CD8 (+) CD25 (+) Foxp3 (+) suppressive T cells in colorectal cancer tissue. Gut 58:520-529.
26. Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, et al. (2008) CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3 (+) regulatory T cells in gastric cancer. International Journal of Cancer 122:2286-2293.
27. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, Powell DJ, Wunderlich JR, et al. (2008) FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 112:4953-4960.
28. Anz D, Koelzer VH, Moder S, Thaler R, Schwerd T, et al. (2010) Immunostimulatory RNA Blocks Suppression by Regulatory T Cells. Journal of Immunology 184:939-946.
29. Ebelt K, Babaryka G, Frankenberger B, Stief CG, Eisenmenger W, et al. (2009) Prostate cancer lesions are surrounded by FOXP3 (+), PD-1 (+) and B7-H1 (+) lymphocyte clusters. European Journal of Cancer 45:1664-1672.
30. Farinha P, Al-Tourah A, Gill K, Klasa R, Connors JM, et al. (2010) The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. Blood 115:289-295.
31. Gobert M, Treilleux I, Bendriss-Vermare N, Bachelot T, Goddard-Leon S, et al. (2009) Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome. Cancer Research 69:2000-2009.
32. Menetrier-Caux C, Gobert M, Caux C (2009) Differences in Tumor Regulatory T-Cell Localization and Activation Status Impact Patient Outcome. Cancer Research 69:7895-7898.
33. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804-811.
34. Wing K, Sakaguchi S (2010) Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nature Immunology 11:7-13.
35. Hinz S, Pagerols-Raluy L, Oberg H-H, Ammerpohl O, Grussel S, et al. (2007) Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67:8344-8350.
36. Ebert LM, Tan BS, Browning J, Svobodova S, Russell SE, et al. (2008) The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 68:3001-3009.
37. Karanikas V, Speletas M, Zamanakou M, Kalala F, Loules G, et al. (2008) Foxp3 expression in human cancer cells. J Transl Med 6:19.
38. Zhang H-Y, Sun H (2010) Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Letters 287:91-97.
39. Zuo T, Wang L, Morrison C, Chang X, Zhang H, et al. (2007) FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129:1275-1286.
40. Wu YQ, Borde M, Heissmeyer V, Feuerer M, Lapan AD, et al. (2006) FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 126:375-387.
41. Shevach EM (2006) From vanilla to 28 flavors: Multiple varieties of T regulatory cells. Immunity 25:195-201.
42. Sakaguchi S (2008) Regulatory T cells in the past and for the future. European Journal of Immunology 38:901-903.
43. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, et al. (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. Journal of Experimental Medicine 203:871-881.
44. Clarke B, Tinker AV, Lee C-H, Subramanian S, van de Rijn M, et al. (2009) Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology 22:393-402.
45. Feyler S, von Lilienfeld-Toal M, Jarmin S, Marles L, Rawstron A, et al. (2009) CD4 (+) CD25 (+) FoxP3 (+) regulatory T cells are increased whilst CD3 (+) CD4 (2) CD8 (2) alpha beta TCR+ Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden. British Journal of Haematology 144:686-695.
46. Chen WJ, Jin WW, Hardegen N, Lei KJ, Li L, et al. (2003) Conversion of peripheral CD4 (+) CD25 (2) naive T cells to CD4 (+) CD25 (+) regulatory T cells by TGF-beta induction of transcription factor Foxp3. Journal of Experimental Medicine 198:1875-1886.
47. Kmieciak M, Gowda M, Graham L, Godder K, Bear HD, et al. (2009) Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. Journal of Translational Medicine 7.
48. Curiel TJ (2007) Tregs and rethinking cancer immunotherapy. Journal of Clinical Investigation 117:1167-1174.
49. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991-998.
50. Dunn GP, Ikeda H, Bruce AT, Koebel C, Uppaluri R, et al. (2005) Interferongamma and cancer immunoediting. Immunol Res 32:231-245.
51. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, et al. (2007) Tumor-derived CD4 (+) CD25 (+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 56:48-59.
52. Liu VC, Wong LY, Jang T, Shah AH, Park I, et al. (2007) Tumor evasion of the immune system by converting CD4 (+) CD25 (2) T cells into CD4 (+) CD25 (+) T regulatory cells: Role of tumor-derived TGF-beta. Journal of Immunology 178:2883-2892.
53. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, et al. (2009) Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Modern Pathology 22:393-402.
54. Zou WP (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nature Reviews Cancer 5:263-274.
55. Le DT, Ladle BH, Lee T, Weiss V, Yao XS, et al. (2011) CD8 (+) Foxp3 (+) tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response. International Journal of Cancer 129:636-647.
56. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. International Journal of Cancer 127:759-767.
57. Rahir G, Moser M (2012) Tumor microenvironment and lymphocyte infiltration. Cancer Immunology Immunotherapy 61:751-759.